Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price fell 11.3% during mid-day trading on Wednesday . The stock traded as low as GBX 5.40 and last traded at GBX 5.50. Approximately 370,638 shares traded hands during mid-day trading, an increase of 39% from the average daily volume of 266,926 shares. The stock had previously closed at GBX 6.20.
Allergy Therapeutics Stock Performance
The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The business’s 50-day moving average is GBX 7.74 and its 200-day moving average is GBX 9.79. The company has a market capitalization of £379.95 million, a PE ratio of -6.19, a PEG ratio of -30.70 and a beta of 0.87.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off?
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
